DGIdb - HALOFUGINONE Drug Record

HALOFUGINONE chembl:CHEMBL1197091 Antineoplastic

Alternate Names:

HALOFUGINONE
HT-100

Drug Info:

FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent

(0 More Sources)

Publications:

Nagler et al., 2004, Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone., Eur. J. Cancer
Gnainsky et al., 2006, Involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis effect of halofuginone., Cell Tissue Res.
Pinthus et al., 2005, Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression., J. Urol.
McGaha et al., 2002, Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts., J. Invest. Dermatol.
Leiba et al., 2006, Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells., J. Leukoc. Biol.

HALOFUGINONE PTP4A1

Interaction Score: 20.61

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16508789

Sources:
NCI
HALOFUGINONE EPRS1

Interaction Score: 20.61

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Novel Target

Trial Name halofuginone ,Tempostatin

PMIDs:
None found

Sources:
TdgClinicalTrial TTD
HALOFUGINONE WT1

Interaction Score: 2.94

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16148645

Sources:
NCI
HALOFUGINONE IL2

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15177499

Sources:
NCI
HALOFUGINONE TNF

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16769768

Sources:
NCI
HALOFUGINONE SMAD3

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11874485

Sources:
NCI

TdgClinicalTrial: HALOFUGINONE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

NCI: HALOFUGINONE

Version: 14-September-2017

Alternate Names:

C1120 NCI drug code

Drug Info:

Publications:

Leiba et al., 2006, Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells., J. Leukoc. Biol.

Nagler et al., 2004, Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone., Eur. J. Cancer

Gnainsky et al., 2006, Involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis effect of halofuginone., Cell Tissue Res.

TTD: HT-100
- Version: 2020.06.01
Alternate Names:

D0U3KP TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1197091
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Novel drug target	Novel Target
Trial Name	halofuginone ,Tempostatin

HALOFUGINONE Drug Record

HALOFUGINONE chembl:CHEMBL1197091 Antineoplastic

Alternate Names:

Drug Info:

Publications:

HALOFUGINONE PTP4A1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16508789

Sources: NCI

HALOFUGINONE EPRS1

Interaction Types & Directionality: n/a

Interaction Info: Novel drug target Novel Target Trial Name halofuginone ,Tempostatin

PMIDs: None found

Sources: TdgClinicalTrial TTD

HALOFUGINONE WT1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16148645

Sources: NCI

HALOFUGINONE IL2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15177499

Sources: NCI

HALOFUGINONE TNF

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16769768

Sources: NCI

HALOFUGINONE SMAD3

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11874485

Sources: NCI

TdgClinicalTrial: HALOFUGINONE

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small molecule FDA Approval not approved

Publications:

NCI: HALOFUGINONE

Alternate Names: C1120 NCI drug code

Drug Info:

TTD: HT-100

Alternate Names: D0U3KP TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1197091

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
16508789

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Novel Target

Trial Name halofuginone ,Tempostatin

PMIDs:
None found

Sources:
TdgClinicalTrial TTD

Interaction Types & Directionality:

n/a

PMIDs:
16148645

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15177499

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16769768

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11874485

Sources:
NCI

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Alternate Names:

C1120 NCI drug code

Alternate Names:

D0U3KP TTD Drug ID